Clarivate Analytics

Clarivate Analytics
Share

Clarivate Analytics

 •  February 14

IP and Standards This article is part of an ongoing State of Innovation series exploring global inventions and innovation trends in 12 key industries. Download the State of Innovation report on the Biotechnology industry now, or download the full 2017 report here. In 2012, there were an estimated 14.1 million new cases of cancer and 8.2 million...

Clarivate Analytics

 •  February 13

Life Sciences Connect This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis was gathered from Clarivate Analytics Cortellis. The unmet need The...

Clarivate Analytics

 •  February 8

Life Sciences Connect The FDA often stresses the importance of enrolling diverse patient populations in clinical trials conducted to support product applications — both in industry guidance documents and during interactions with product sponsors. In Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical...

Clarivate Analytics

 •  February 6

Life Sciences Connect In news releases issued by the U.S. Food and Drug Administration (FDA), “firsts” always catch the eye. Because the majority of prescriptions in the U.S. are dispensed with generic medications, announcements of new “first generics” are especially noteworthy. These products are the first approval by the FDA that permits a...

Clarivate Analytics

 •  January 25

Science Research Connect Timely recommendation for drug reimbursement by health technology assessment (HTA) agencies is critical to ensuring patient access to the medicines they need, a study by the Centre for Innovation in Regulatory Science (CIRS) has confirmed. As part of an ongoing effort to monitor regulatory and HTA performance, CIRS...

Clarivate Analytics

 •  January 22

Life Sciences Connect When the DIA’s Middle East Regulatory Conference convened in Kuwait late last year, an array of hot topics drew considerable discussion. The gathering, which brings together multiple stakeholders from multinational companies, local manufacturers and agents/distributors with representatives of health authorities from across the...

Clarivate Analytics

 •  January 17

Life Sciences Connect This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis was gathered from Clarivate Analytics Cortellis. According to the...

Clarivate Analytics

 •  January 9

Life Sciences Connect The possibilities Disease forecasts are market analytics, aimed at understanding and predicting a product’s market potential. Prediction modelling usually involves a prediction profile (algorithm) from past studies. The model is then “deployed” so that a new individual can get a prediction instantly for whatever the need be,...

Clarivate Analytics

 •  January 9

IP Solutions Innovation is taking off again in the pharmaceutical industry with a healthy 20 percent growth in patents published in 2016. This follows a period of intense realignments, consolidations, mergers and acquisitions driven by the loss of patent protection for many blockbusters owned by the major companies and the consequent increase in...

Clarivate Analytics

 •  January 2

Social media has transformed the way brands interact and engage with consumers and, as part of that change, opened up a new avenue for the sale of counterfeit goods. Scammers leverage social platforms to impersonate brands by repurposing legitimate images, brands names and logos to appear credible before promoting fake goods and directing consumers...